© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma
Daratumumab Leads to Deep Responses Among Newly Diagnosed Black Patients With Multiple Myeloma
September 10, 2020
Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.
CLR 131 Continues to Show Encouraging Responses in Triple Refractory Multiple Myeloma
September 09, 2020
CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.
FDA Grants Priority Review to Melflufen for Triple-Class Refractory Multiple Myeloma
August 31, 2020
The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Ganguly Details Treatments for Standard-Risk Multiple Myeloma
August 28, 2020
Siddhartha Ganguly, MD, reviewed the case of a 51-year-old man with standard-risk multiple myeloma.
Gasparetto Addresses Triplet Versus Doublet Induction Options in Multiple Myeloma
August 21, 2020
During a virtual Case Based Peer Perspective event, Cristina Gasparetto, MD, discussed the case of a geriatric male diagnosed with stage II multiple myeloma.
FDA Approves Daratumumab Plus Kd Regimen in Relapsed/Refractory Multiple Myeloma
August 20, 2020
The FDA granted approval to the combination of daratumumab plus carfilzomib and dexamethasone as treatment of adult patients with relapsed or refractory multiple myeloma who have received up to 3 prior lines of therapy.
Berdeja Compares Later-Line Therapies in Multiple Myeloma
August 17, 2020
As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient.
Exploring Challenges With CAR T Cells and NK Cells in Multiple Myeloma
August 10, 2020
C. Ola Landgren, MD, PhD, discusses the use of chimeric antigen receptor T cells and CAR natural killer cells in the multiple myeloma setting.
New Analysis of Somatic Alterations Identifies Low-Risk Multiple Myeloma Subgroup
August 08, 2020
A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.
Highlighting Therapeutic Options in Later Lines for Multiple Myeloma
August 06, 2020
Kenneth C. Anderson, MD, discusses the therapies for patients who have multiple myeloma and have developed drug resistance.